Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Editas Medicine Appoints John D. Mendlein to Board of Directors

Editas Medicine, a genome editing company based in Cambridge, Mass, has appointed John D. Mendlein to its board of directors. Mendlein has served as CEO of aTyr Pharma since 2011, as well as executive chairman for the company from July 2010 to January 2016.

Read the full article…

Posted in Board Director Appointments | Tagged , , , , , , , , , | Leave a comment

Intellia Appoints Caroline Dorsa to Board of Directors

Intellia Therapeutics, a genome editing company based in Cambridge, Massachusetts, has named Caroline Dorsa to its Board of Directors. Her appointment will help advance the company’s mission of developing therapeutics utilizing CRISPR/Cas9 gene-editing technology.Watch Full Movie Online Streaming Online and Download

Read the full article…

Posted in Board Director Appointments | Tagged , , , , , , , , , | Leave a comment

Vertex and CRISPR Therapeutics Form Research Collaboration

BOSTON & CAMBRIDGE, Massachusetts – Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced that the two companies have entered into a strategic research collaboration focused on the use of CRISPR’s gene editing technology, known as CRISPR-Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. The collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases where targets have been validated through human genetics. Vertex and CRISPR will focus their initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to cystic fibrosis and sickle cell disease. Vertex and CRISPR will also evaluate a specified number of other genetic targets as part of the collaboration. Vertex will have exclusive rights to license up to six new CRISPR-Cas9-based treatments that emerge from the collaboration. As part of the collaboration, Vertex made an up-front commitment of $105 million to CRISPR, including $75 million in cash and a $30 million equity investment. CRISPR is also eligible to receive future development, regulatory and sales milestones and royalty payments on future sales.

Read the full article…

Posted in Pharmaceutical business | Tagged , , , , , , , , , | Leave a comment

Editas adds CFO and $120m in Series B round

Editas Medicine, a leading genome editing company, today announced that it has raised $120 million in a highly oversubscribed Series B private financing. The financing assembles a broad syndicate of leading public and private investors who underpin many of the most innovative biopharmaceutical and technology companies.

Read the full article…

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap